Since last summer, the market has distributed indiscriminate beatings across the biotechnology industry, and companies without approved products to sell have been hardest hit. The iShares Biotechnology ETF (NASDAQ: IBB), which tracks hundreds of biotech stocks, has rebounded from low points seen earlier this summer, but it's still 25% lower than where it stood a year ago.
Plenty of biotech stocks remain on sale, you just have to know where to look.Cellular metabolism specialistAgios Pharmaceuticals (NASDAQ: AGIO)has three candidates under development with its deep-pocketed partner,Celgene (NASDAQ: CELG), and a wholly owned orphan drug nearing the finish line.
Plenty of biotech stocks remain on sale, you just have to know where to look.Cellular metabolism specialistAgios Pharmaceuticals (NASDAQ: AGIO)has three candidates under development with its deep-pocketed partner,Celgene (NASDAQ: CELG), and a wholly owned orphan drug nearing the finish line.
